Boston Scientific Corporation Announces Collaboration withBolt MedicalReached a final acquisition agreement, Boston Scientific will acquire for $6.64 billionBolt Medical. This6.6$400 Million Acquisition Price by$443 million upfront payment (74% equity, before the acquisition Boston Scientific held 26% equity) and2.2The $100 million milestone reward constitutes.“Intravascular Lithotripsy with Shock Waves"It is one of the fastest-growing fields in medical devices, addressing a significant unmet need for patients with complex calcified arterial disease through minimally invasive methods. Bolt Medical is developing a next-generation technology that is highly complementary to our existing product portfolio. Adding this system to our offerings can help us better serve physicians and their patients while providing a platform for future innovation."---Lance Bates Senior Vice President and President of Boston Scientific's Interventional Cardiology DivisionBolt MedicalThe core product BoltThe initial concept product of IVL was developed by Boston Scientific and established in 2019 based on the Bolt IVL concept product.Bolt Medical. AsBolt MedicalAs a strategic investor, Boston Scientific Corporation holds approximately 26% of the equity.InIntravascular Lithotripsy (In the IVL field, Boston Scientific was once the most promising to become the industry leader. Unfortunately, due to limited financial resources, it eventually failed to compete with others.Shockwave Ties the Knot.Shockwave was also acquired by its long-time rival Johnson & Johnson last year for $13.1 billion.As Johnson & Johnson acquires Shockwave, it propels J&J back into the top three in cardiovascular (while Boston Scientific falls out of the top three). Therefore, whether driven by market demand (second only to the growth rate of the PFA market) or based on its long-standing rivalry with J&J, Boston Scientific has every reason to strategize.IVL Market.
Therefore, in the acquisitionShockwaAfter VE fails, Boston Scientific immediately implements an alternative solution.Bolt Medical，allowing oneself to stay at the forefront of the IVL field (and share in this rapidly growing large market).Currently, IVL has become the second largest market after PFA. Three of the four major cardiovascular companies have entered the market, just waiting for the leading cardiovascular company to join the competition.Among all the IVL latecomers, Boston Scientific is most likely to become Johnson & Johnson's strongest competitor. CurrentlyBolt MedicalTwo peripheral clinical studies (RESTORE ATK and RESTORE BTK) have been completed, and submissions to the FDA and CE will be made soon.Bolt IVLMarket approval. Meanwhile, the FDA approved last month.Bolt IVLIDE Study for the Treatment of Coronary Artery Calcification.
Bolt IVL
Bolt IVLIt is an innovative shockwave balloon product designed to disrupt the intima and deep calcium by generating acoustic pressure waves within the balloon catheter. It also features enhanced deliverability, a highly navigable catheter, and visible directional emitters to consistently provide energy for the treatment of concentric and eccentric cardiovascular calcified lesions.
Bolt IVLUnlike Shockwave IVL, which uses laser-based IVL technology, the laser energy is distributed through optical fibers to multiple locations within the balloon and then applied via the balloon.The plasma generated internally is converted into a shock wave, thereby achievingEffect of Intravascular Lithotripsy.
Principle of Shock Waves in Laser Products
Bolt IVL Clinical
Bolt MedicalIn May of this year, an announcement was made regardingBolt IVLClinical Study on the Treatment of Above-the-Knee Calcified Lesions (RESTORE ATK).
Among 60 cases, there were no reports of MAE within 30 days after surgery, including severe dissection, perforation, or unplanned major amputation of the target limb, as well as no clinically-driven target lesion revascularization.
PI Evaluation
"The RESTORE ATK trial demonstrated excellent safety and efficacy in 60 reported patients within 30 days. I amBolt IVLThe results were particularly impressive, as the enrolled patients had severe calcification, and 26% of the lesions were chronic total occlusions.Bolt IVL's enhanced pulses and targeted therapy provide progress in addressing unmet needs in IVL treatment, allowing for independent IVL treatment of these complex patients, importantly.The required post-expansion rate is as low as 12%.。”
---Marianne Brodmann Medical University of Graz
Bolt IVL In Vitro Demonstration
Bolt MedicalIt is an innovative medical device company that focuses on designing and developing innovative IVL catheters for coronary and peripheral interventional procedures, specifically for patients with moderate to severe calcified arterial disease.
